In what CEO Ken Cunningham called a "major milestone," the UK's SkyePharma filed for FDA approval of its asthma drug Flutiform. Flutiform is SkyePharma's biggest drug prospect, with estimated annual sales of $500 million. SkyePharma hopes to find a solid perch for the drug in a market that faces major changes as generic versions of Advair and Symbicort arrive alongside new-gen asthma treatments. SkyePharma release